CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 32 enrolled
Drug / intervention
Nivolumab +4 moredrug
Likely dose
Nivolumab 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03044613
NCT03044613Phase 1Active
CompareCT.gov

Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Feb 7, 2017·Updated Mar 23, 2026

In Brief

A Phase 1 clinical trial evaluating Nivolumab, Relatlimab, and 3 other interventions for Gastric Cancer and 2 related conditions. Active but no longer recruiting, targeting 32 participants across 3 sites.

Detailed Summary

Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer and will change cellular and molecular characteristics of the tumor microenvironment that will improve survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 1Active
20172018201920202021202220232024202520262027
First PostedFeb 7, 2017
Enrollment StartJul 11, 2017
Primary CompletionMar 1, 2027
Study CompletionAug 1, 2027
TodayJul 2, 2026
Enrollment to primary: 9.6 yearsPosted 9.4 years agoPrimary completion in 8 months

Interventions

Nivolumabdrug

240mg or 1 mg/kg administered IV

Relatlimabdrug

80mg administered IV

Carboplatindrug

standard care dose

Paclitaxeldrug

standard care dose

Radiationradiation

standard care dose